Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
| Autor: | Farnier, Michel, Jones, Peter, Severance, Randall, Averna, Maurizio, Steinhagen-Thiessen, Elisabeth, Colhoun, Helen M., Du, Yunling, Hanotin, Corinne, Donahue, Stephen |
|---|---|
| Zdroj: | In Atherosclerosis January 2016 244:138-146 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect